肝细胞癌切除术后治愈概率的多机构分析:BCLC指南内外的定义
该多机构回顾性研究纳入1998至2017年间1010例接受治愈性肝切除术的肝细胞癌患者,采用非混合治愈模型估算治愈比例。结果显示总治愈概率为42.2%,中位治愈时间3.35年;术前甲胎蛋白、肿瘤大小、数目及切缘状态为独立预测因素。BCLC-A患者治愈概率47.6%,BCLC-B患者37.6%。
要点
- 肝细胞癌切除术后约42.2%患者可达到治愈,中位治愈时间3.35年。
- 甲胎蛋白≤10 ng/mL、肿瘤≤5 cm、≤3个结节且R0切除者治愈概率达61.6%。
- BCLC-B患者仍可获得37.6%的治愈概率,选择患者手术有意义。
核心结论
- 约四成肝细胞癌患者肝切除术后可视为治愈。
- BCLC-A患者治愈概率高于BCLC-B,但部分BCLC-B患者手术仍提供合理治愈可能。
研究设计与样本
- 国际多机构数据库回顾性队列研究,纳入1998至2017年间1010例接受治愈性肝切除术的肝细胞癌患者。
- 采用非混合治愈模型,以无病生存为主要指标,按年龄、种族和性别与一般人群匹配后估算治愈比例。
主要发现
- 中位无病生存期为2.8年,5年无病生存率为36.6%。
- 总治愈概率为42.2%,中位治愈时间3.35年。
- 多变量治愈模型显示术前甲胎蛋白水平、肿瘤大小、肿瘤数目和切缘状态是治愈的独立预测因素。
- 甲胎蛋白≤10 ng/mL、最大肿瘤≤5 cm、结节≤3个且R0切除的患者治愈比例为61.6%。
- 具有全部4项不利预后因素(甲胎蛋白>11 ng/mL、结节≥4个、大小>5 cm、R1切除)的患者治愈比例为15.8%。
关键数值与推荐
- BCLC-A患者治愈概率为47.6%,BCLC-B患者治愈比例为37.6%。
- 在BCLC-B患者中,仅甲胎蛋白水平可预测治愈概率。
临床怎么用
- 术前可综合甲胎蛋白、肿瘤大小、数目及切缘状态评估治愈概率,辅助手术决策。
- 对BCLC-B患者,若甲胎蛋白等指标有利,仍可考虑切除以争取治愈机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgery is considered the only potentially curative treatment option for patients with hepatocellular carcinoma. However, the chance that patients will eventually be "cured" after liver resection for hepatocellular carcinoma remains ill defined. METHODS: Patients who underwent curative-intent hepatectomy for hepatocellular carcinoma between 1998 and 2017 were identified using an international multi-institutional database. A nonmixture cure model was used with disease-free survival as a primary measure to estimate cure fractions after matching patients with the general population by age, race, and sex. RESULTS: Among 1,010 patients, the median and 5-year disease-free survival were 2.8 years and 36.6%, respectively. The probability of being cured after hepatocellular carcinoma resection was 42.2% and the median time to cure was 3.35 years. The multivariable cure model revealed preoperative alpha-fetoprotein level, tumor size, tumor number, and margin status as independent predictors of cure. The cure fraction for patients with an alpha-fetoprotein level ≤ 10 ng/mL, largest tumor size ≤5 cm, ≤3 nodules, and R0 resection was 61.6%. In contrast, patients who had all 4 unfavorable prognostic factors (ie, alpha-fetoprotein >11 ng/mL, nodules ≥4, size >5cm, R1 resection) had a cure fraction of 15.8%. Although the probability of cure was 47.6% among Barcelona Clinic Liver Cancer-A patients, patients undergoing resection for Barcelona Clinic Liver Cancer-B hepatocellular carcinoma had a 37.6% cure fraction. Only alpha-fetoprotein levels predicted the probability of cure among Barcelona Clinic Liver Cancer-B patients. CONCLUSION: Roughly 4 in 10 patients could be considered "cured" after liver resection for hepatocellular carcinoma. Although cure was achieved more often after resection for Barcelona Clinic Liver Cancer-A hepatocellular carcinoma, surgery still provided a reasonable probability of cure among select patients with Barcelona Clinic Liver Cancer-B hepatocellular carcinoma.
引用
- Tsilimigras DI, Bagante F, Moris D, et al. Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients. Surgery. 2019. PMID: 31606196. doi:10.1016/j.surg.2019.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。